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To assess the awareness, knowledge, use, and willingness to use and need of PrEP among
men who have sex with men (MSM) and transgender women (TW) who attended World Gay
Pride (WGP) 2017 in Madrid.
Design and methods
Online survey. Participants were recruited through gay-oriented dating apps and HIV Non-
Governmental Organizations´ social media. Inclusion criteria included being MSM or TW,
age 18 years old or above, and having attended WGP in Madrid. Information regarding the
participant’s awareness and knowledge, use or willingness to use, and need for PrEP was
collected, as well as sociodemographic characteristics. Participants were considered to be
in need of PrEP if they met one of the following indication criteria: having practiced unpro-
tected anal intercourse with more than 2 partners, having practiced chemsex, or having
engaged in commercial sex—all in the preceding 6 months. Descriptive and multivariable
analyses with logistic regression were conducted.
Results
472 participants met the inclusion criteria and completed the questionnaire. The mean age
was 38, 97.7% were MSM, 77% had a university education, and 85% were living in Spain,
mostly in big cities. Overall, 64% of participants were aware of PrEP, but only 33% knew cor-
rectly what PrEP was. 67% of HIV-negative participants were willing to take PrEP, although
only 5% were taking it during WGP, mostly due to lack of access. 43% of HIV-negative
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respondents met at least one PrEP indication criteria. For HIV-negative men living in Spain,
university education and living in big cities was associated with PrEP awareness. Lower
education level and meeting PrEP criteria was associated with willingness to use PrEP.
Conclusions
Our study shows that among MSM attending WGP 2017 in Madrid, there was limited PrEP
awareness, low accuracy of PrEP knowledge, and a high need and willingness to use PrEP.
Health authorities should strengthen existing preventive strategies and implement PrEP.
Introduction
Sexually transmitted HIV remains an important public health issue in Spain. In 2016, out of
the 3353 new HIV diagnoses, 53.1% were men who have sex with men (MSM). While HIV
incidence has steadily decreased around the globe since 2009, it has remained stable for MSM
at rates ranging from 10–12 new cases per 100,000 men [1].
In order to reverse this trend, the Spanish National AIDS Plan recommends promoting
condom use, HIV testing, rapid access to Antiretroviral Therapy (ART), and Post-exposure
Prophylaxis (PEP) [2]. However, it has been strongly demonstrated that condoms are not used
consistently among some groups of MSM who are at high risk of being infected with HIV
[3,4]. Overall, undiagnosed HIV is estimated to be between 14% and 22% of people living with
HIV [5]. Although PEP is available and free in public hospital’s emergency rooms, there is a
lack of awareness and use of it [6].
In this context, Pre-Exposure Prophylaxis (PrEP) could be an additional and effective pre-
ventive measure that, unfortunately, is not yet formally available in Spain. The pre-exposure
prophylactic use of the commercial combination of tenofovir/emtricitabine has been approved
by the European Medicines Agency [7] and has already been implemented in European coun-
tries with epidemiological patterns similar to Spain’s [8]—showing to be effective, safe, and
cost-effective [9–12]. In Spain, the Agency of Medicines and Medical Devices (AEMPS) has
also approved the commercial combination of tenofovir/emtricitabine for PrEP indication as
part of a comprehensive prevention program [13]. The National Ethics Committee issued a
statement in favour of PrEP public funding in March 2017 [14]. In June 2016, the Spanish Sci-
entific Clinical Society for AIDS (GeSIDA) issued a PrEP recommendation document to facili-
tate the way forward [15], followed by another from the National AIDS Plan at the Ministry of
Health (MoH) [16]. These documents recommend PrEP for populations most at risk of
acquiring HIV, especially MSM and transgender women (TW). However, the Spanish MoH
and its equivalent health authorities in the Autonomous Communities have not implemented
PrEP, thus it is not available within the Spanish Health System [17].
Additionally, Madrid was hosting the celebration of World Gay Pride (WGP) between the
22nd of June and the 2nd of July 2017. Estimated attendance was 3 million people, mostly
MSM, coming from a number of countries, possibly some of them prescribing PrEP. Apart
from the cultural events and the official parade, many gay-oriented clubs and saunas were pro-
graming sex parties during Gay Pride week. An increased need for PrEP and an increase in
PrEP use were expected among WGP attendees.
The aim of this work was to assess awareness, knowledge, use of PrEP, willingness to use
PrEP, and PrEP need among MSM and TW attending WGP 2017 in the city of Madrid
between June 23nd and July 2nd.
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Materials and methods
This study was approved by the Carlos III Health Institute Research Ethics Committee.
Design of the questionnaire
An electronic survey with a structured questionnaire was designed using questionnaires from
previous PrEP studies [11], the Spanish Sexual Health Survey [18], and GeSIDA PrEP Guide-
lines [15]. It was reviewed by a group of 9 experts. The questionnaire included a welcome mes-
sage in which participants were informed about the objectives of the study and were asked for
their consent to participate. The survey was advertised through gay-oriented dating apps and
the social media of HIV Non-Governmental Organizations (NGO) June 26th and August 8th of
2017, showing the following messages: “Are you PrEPared for the pill that prevents HIV? /
Help us to improve the health of LGBT community by answering some questions / Are you
PrEPared for World Pride?” The questionnaire was available in Spanish, English, Russian, Ital-
ian, and French. Participants self-completed the questionnaire. Inclusion criteria for partici-
pants was: being MSM or TW, over 18 years old, and having attended WGP in Madrid.
Definition of variables
Information collected in the questionnaire permitted the creation the five variables of interest
(PrEP awareness, PrEP knowledge, PrEP use, willingness to use PrEP, and PrEP need) and the
variables of exposure: age, gender identity, sexual orientation, educational level, place of resi-
dence, HIV status, and number of inhabitants in place of residence (only for those living in
Spain). Participants were considered MSM if they were cisgender men who had sex with cis-
gender men.
PrEP awareness was assessed by asking participants if they knew of “the so-called Pre Expo-
sure Prophylaxis (PrEP)”. PrEP knowledge was assessed using multiple true-false questions in
which participants had to mark true among the following: i) It is a pill; ii) It reduces the risk of
getting HIV. The other true-false questions were: iii) It is an injection; iv) It can be used after
you believe you have had high-risk sex with the possibility of becoming infected with HIV; v)
It reduces the risk of getting HIV and other sexually transmitted infections (STI). Only partici-
pants who marked options i and ii as true and did not mark options iii, iv, and v as true were
considered to have accurate knowledge of PrEP.
PrEP was described as “a pill that, if you take it, protects you from getting HIV even if you
have sex with a person who has HIV. PrEP does not protect against other STI, only HIV” to
respondents who were not aware of PrEP and to respondents who were aware of PrEP but had
never used it.
We considered participants to be in PrEP need if they met one of the following indication
criteria: having practiced unprotected anal intercourse with more than 2 partners, having prac-
ticed Chemsex, or having engaged in commercial sex—all in the preceding 6-months as
recorded in GeSIDA PrEP Guidelines [15]. Other PrEP indication criteria, such as STI diagno-
sis or PEP use, were not considered due to the difficulties of self-reporting these variables and
to ensure completion of the questionnaire by keeping it brief. Data are available in the support-
ing information S1 File.
Sampling, size of the simple and analysis strategy
We estimated that a sample size of 385 participants would be needed in order to assess PrEP
use considering an expected PrEP use of 50% (worst-case scenario) and a bilateral precision of
five points.
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Descriptive analyses were conducted for all interest variables (PrEP awareness, PrEP knowl-
edge, PrEP use, willingness to use PrEP, PrEP need) and exposure variables. Chi-square, Fish-
er’s exact tests, and Wilcoxon rank-sum tests were used to identify differences between four of
the main outcomes: PrEP awareness, PrEP use and willingness to use PrEP (collapsed in one
single variable as it was considered that being in use of PrEP was equivalent to be willing to use
PrEP) and PrEP need. Multi-variable logistic regression was developed in order to identify
which variables of exposure were associated with PrEP awareness, PrEP use or willingness to
use, and PrEP need for a subsample of MSM living in Spain. PrEP awareness was considered
as a variable of exposure for PrEP use or willingness to use and for PrEP need. Likewise, PrEP
need was considered a variable of exposure for PrEP use or willingness to use. HIV+ individu-
als were not considered in the analysis of factors associated with PrEP need and use or willing-
ness to use PrEP.
We used multivariable logistic regression to calculate odds ratios (OR) and 95% confidence
intervals (CI) for the association between the three main outcomes and predictive factors. An
explanatory modelling was performed following a stepwise backward strategy, following the
Akaike Information Criterion (AIC) and the Wald Test p-values. We selected the model with
highest significance (Wald test p-values under 0.05) and the best goodness-of-fit (lowest AIC
value) [19]. The assumptions for the logistic regression model were checked. All statistical
analyses were performed using Stata software (version 14.0; Stata Corporation, College Station,
Texas, USA).
Results
Of the 1,269 people that accessed the questionnaire, 1,006 completed it and 472 met the inclu-
sion criteria. The most frequent exclusion criteria was not attending WGP (379), followed by
not consenting to participate in the study after being asked (114). Participants who did not
complete the questionnaire were significantly older than those who did. No other information
was available for this group (data not shown). Almost all respondents were MSM, most of
whom were living in Spain and had a university education. The majority of participants
declared they did not live with HIV (Table 1).
PrEP awareness and knowledge
About two out of 3 participants (64%) were aware of PrEP, but only 33% correctly knew what
PrEP was. Higher educational levels and living in cities with larger populations were indepen-
dently associated with PrEP awareness among HIV-negative men living in Spain (Table 2).
PrEP use and willingness to use
Only HIV-negative participants aware of PrEP (n = 215) were asked about PrEP use. Among
them, 17 (8%) used PrEP during WGP, mainly prescribed by a doctor (n = 6) or purchased on
the internet (n = 4). Other modes of acquisition (n = 7) included enrolment in clinical trials,
emergency rooms, or through a prescription for indications other than PrEP, largely PEP.
Only 9 out of the 17 PrEP users were living in Spain. The remaining 198 participants did not
use PrEP during WGP due to a lack of access (45%), a lack of willingness (39%), and other rea-
sons (16%).
In total, 67% of HIV-negative participants were using or would use PrEP. For men living in
Spain, use of or willingness to use PrEP was 68%. Willingness to use PrEP was high among
HIV-negative participants: 63% of them (n = 212) would use PrEP, mainly to prevent HIV
(53%), to have unprotected sexual intercourse (14%), or to feel safer during sex (8%). The
main reasons to reject PrEP (n = 112) were condom preference (22%), lack of prevention of
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Table 1. Characteristics of the sample (n = 472).
% (n)
Age (m, SD) 38 (9.44)
Age groups
18–25 years old 9.3 (44)
26–25 years old 31.6 (149)
36–45 years old 35.0 (165)
More than 45 years old 24.2 (114)
Gender identity
Cisgender Man 98.5 (465)
Transgender Man 0.6 (3)






University or more 77.3 (107)
High school or less 22.7 (365)
Place of residence
Spain 85.4 (403)
Latin America or Caribbean 3.0 (14)
Another countries in Europe 10.2 (48)
North America 0.4 (2)
Unknown 1.1 (5)
Inhabitants in place of residence��
More than 500,000 66 (266)
Between 100,000 and 500,000 12.7 (51)
Between 50,000 and 100,000 7.0 (28)
Between 10,000 and 50,000 6.0 (24)




Not living with HIV 71.8 (339)
Don’t know 11.4 (54)
Prefer not to say 2.5 (12)
Are aware of PrEP
Yes 64.19 (303)
No 35.81 (169)
Know what PrEP is ���
Yes 32.63 (154)
No 31.57 (149)




� Considering MSM as cisgender men that have sex with another cisgender men.
��Among those living in Spain.
���Among those being aware of PrEP
���� Meet PrEP criteria (among those who reported not be living with HIV)
https://doi.org/10.1371/journal.pone.0204738.t001
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other STIs (19%), or having a steady partner (13%). Only two participants reported not want-
ing to use PrEP for economic reasons. In the multivariable analyses, meeting PrEP criteria
(aOR = 2.67) and not having a university education (aOR = 0.52) were independently associ-
ated to using or willingness to use PrEP (Table 2).
PrEP need
Of the 339 participants not living with HIV, 43% met at least one of the PrEP indication crite-
ria considered in this study [12]. Among them, 84% had unprotected anal intercourse with
three or more partners, 51% practiced chemsex, and 16% engaged in commercial sex in the
previous 6 months (these categories are not mutually exclusive). We did not find any statisti-
cally significant difference in PrEP indication criteria regarding age, education, number of
inhabitants in place of residence, and PrEP awareness (Table 2).
Discussion
Awareness was higher among people living with HIV (PLHIV), people with university educa-
tion, and people living in big cities. This may reflect barriers to access information among
MSM with lower education levels and MSM who live in smaller cities. This creates a situation
Table 2. Variables associated to PrEP awareness, use or willingness to use PrEP, and need of PrEP for MSM living in Spain.
Are aware of PrEP (n = 397) Are using or willing to use PrEP
(n = 286) �
PrEP need (n = 286) �
% (n) p value aOR (IC 95%) % (n) p value aOR (IC 95%) % (n) p value aOR (IC 95%)
Age 64.1 (25) 0.379 . . .
18–25 years old 69.05 (87) 0.379 . . . 48 (12) 0.075 . . . 48 (12) 0.836 . . .
26–35 years old 60.81 (90) . . . 64.6 (62) . . . 39.2 (38) . . .
36–45 years old 58.33 (49) . . . 69.7 (76) . . . 38.5 (42) . . .
More than 45 years old 76.4 (42) . . . 41.8 (23) . . .
Education 46.15 (42) <0.001 Reference
High school or less 68.3 (209) <0.001 2.64 (1.50–4.67) 78.3 (54) 0.028 Reference 47.1 (33) 0.207 . . .
University or more 63.9 (138) 0.52 (0.27–0.99) 38.0 (82) . . .
Inhabitants in place of residence 69.35 (181) <0.001 Reference . . .
More than 500,000 44 (22) <0.001 0.35 (0.17–0.71) 64.7 (119) 0.230 . . . 39.7 (73) 0.884 . . .
Between 500,000 and 100,000 53.66 (44) 0.44 (0.24–0.82) 78.1 (32) . . . 39.0 (16) . . .
Less than 100,000 70.2 (40) . . . 43.1 (25) . . .
HIV status 61.54 (176) 0.002 . . .
Not living with HIV 83.02 (44) 0.002 . . . . . . . . . . . . . . . . . . . . .
PLWHIV 47.92 (23) . . . . . . . . . . . . . . . . . . . . .
Don’t know 80 (8) . . . . . . . . . . . . . . . . . . . . .
Prefer not to say . . . . . . . . . . . . . . . . . .
Are aware of PrEP . . . . . . . . .
Yes . . . . . . . . . 64.6 (113) 0.204 . . . 41.5 (73) 0.580 . . .
No 71.8 (79) . . . 38.2 (42) . . .
Need PrEP . . . . . . . . .
No . . . . . . . . . 79.8 (91) <0.001 Reference . . . . . . . . .
Yes 64.1 (25) 0.379 . . . 59.1 (101) 2.67 (1.54–4.65) . . . . . . . . .
� Participants who reported to be living with HIV were not considered
https://doi.org/10.1371/journal.pone.0204738.t002
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of increased vulnerability, which has already been described for theLGBT community. For
example, there is a relationship between low education levels and late HIV diagnosis across dif-
ferent European countries [20]. Additionally, we did not reach a sufficient number of TW to
extract conclusions about this group. This reflects higher difficulty in reaching this population,
and the need to conduct specific studies to assess how PrEP implementation strategies would
work for TW. All these determinants, which possibly foster health inequalities, need to be
taken into account when developing PrEP implementation policies.
Regarding overall PrEP awareness, recent studies in European contexts similar to ours
show different values: 42% for MSM attendees at Gay Pride in Lisbon 2010 [21]; 85% for MSM
users of sex-dating applications in London [22]; 54% for HIV- MSM from the Amsterdam
Cohort Study for AIDS and HIV in 2015 [23]; 35% for MSM who had unprotected anal inter-
course in 2016 from Scotland, Wales, and Ireland [24]. Although these data refer to prior PrEP
implementation contexts, differences across these European cities may be explained by local
factors, such as support for PrEP from community and administration levels. In Spain, our
results were higher than those reported by the Ferrer et al. study, who found a PrEP awareness
of 29% for MSM recruited online or in HIV testing clinics in Spain 2013–2014 [25]. Despite
the increase in PrEP awareness, PrEP knowledge was low. From our point of view, this could
be related to the fact that very few official information campaigns have been conducted by the
Ministry of Health or other health authorities within the last few years—neither informing the
public about PrEP strategy itself or its political and legal situation, which still remains unclear.
However, we found a considerably high willingness to use PrEP and (like awareness) it was
higher than the one assessed by Ferrer et al (58%) in Spain 2013–14 [26]. This number is prob-
lematic since PrEP knowledge was poor in our sample and the information provided was lim-
ited to participants who were not aware of PrEP. This limitation could have overestimated the
willingness to use PrEP: we did not know if participants would have responded differently had
they been better informed about possible side effects or had greater knowledge of PrEP.
Despite this limitation, we observed that people who met PrEP criteria were more likely to be
willing to use PrEP. This demonstrates that, despite low knowledge, the most at-risk people
could identify PrEP as a useful strategy to reduce the risk of being infected with HIV. This
information could facilitate a strategy to reach the most at-risk groups when PrEP is approved
in Spain. The relationship between PrEP indication criteria and risk of acquiring HIV has
already been shown by Ayerdi et al, who found that a high proportion of new HIV cases diag-
nosed in 2014 at the most important STI clinic in Madrid met PrEP criteria [27]. The relation-
ship between high-risk behavior and willingness to use PrEP has also been shown before
[22,23,27].
Although most of the participants were willing to use PrEP, 33% of them were not. Having
a university education was associated to lower use of or willingness to use PrEP. Further
research is needed to understand this association that has been described in similar contexts
[28], as well as for other factors that could lead to less willingness to use PrEP. Our findings
suggest that PrEP may be perceived as less useful for MSM of higher socio-economic status. It
is necessary to understand if PrEP-related stigma, described in similar contexts [29] could be
related to this perception.
Since participants were self-selected, people who participated in this survey could have
greater knowledge or willingness to use PrEP (selection bias). Awareness, knowledge, use of,
and willingness to use PrEP could be overestimated in our study. We acknowledge that we
asked about unprotected sex instead of condomless sex, which could overestimate the propor-
tion of people having condomless sex as participants replied using their own definition of
unprotected sex. Furthermore, we did not take not into account other GeSIDA indication crite-
ria (diagnosis of STI, administration of PEP, serodiscordant couple without clinical monitoring,
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and injected drug use within last 6 months) [15] which could underestimate the number of peo-
ple at high-risk of being infected with HIV during WGP. Nevertheless, to our knowledge this is
the first work in Spain that correlates a willingness to use PrEP with meeting PrEP criteria, and
the first to address PrEP need among attendees to WGP celebration. This work could help
implement a PrEP strategy and could ease the planning of upcoming, similar events.
In summary, the number of participants who met PrEP criteria was high, indicating that
the risk of acquiring HIV is equally and worryingly high. Although knowledge of PrEP was
limited, a high proportion of MSM living in Spain, especially those most at-risk of acquiring
HIV, was willing to use PrEP. Health authorities should strengthen existing preventive strate-
gies and implement PrEP in order to reduce the number of new HIV cases.
Supporting information
S1 File. Data set.
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